Surgery for prostate cancer: Rationale, technique and outcomes

Cancer and Metastasis Reviews

Volumn 21, Issue 1, 2002, Pages 29-44

  Downs, Tracy M ^a   Kane, Christopher J ^a   Grossfeld, Gary D ^a   Meng, Maxwell V ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Prostate cancer; Prostatectomy; Technique and outcomes

Indexed keywords

FLUTAMIDE; LEUPRORELIN;

ADJUVANT CHEMOTHERAPY; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HEART INFARCTION; HUMAN; INCISIONAL HERNIA; INGUINAL HERNIA; LAPAROSCOPIC SURGERY; LUNG EMBOLISM; LYMPH NODE METASTASIS; MALIGNANT NEOPLASTIC DISEASE; OUTCOMES RESEARCH; PATIENT SELECTION; PELVIS LYMPHADENECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW; SEXUAL DYSFUNCTION; SURGICAL TECHNIQUE; TREATMENT OUTCOME; URINARY DYSFUNCTION;

HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0036403267     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020164206406     Document Type: Review

References (104)

1. Walsh PC: Prostate cancer kills: Strategy to reduce deaths (see comments). Urology 44: 463-466, 1994
2. Thompson IM: Counseling patients with newly diagnosed prostate cancer. Oncology (Huntingt) 14: 119-126, 131; Discussion 135-136, 2000
3. Amling CL, Leibovich BC, Lerner SE, Bergstralh EJ, Blute ML, Myers RP, Zincke H: Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Semin Urol Oncol 15: 215-221, 1997
4. Koppie TM, Grossfeld GD, Miller D, Yu J, Stier D, Broering JM, Lubeck D, Henning JM, Flanders SC, Carroll PR: (in press) Patterns of treatment in patients with prostate cancer initially managed with surveillance: results from the CaPSURE database. J Urol
5. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP: Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer (see comments). J Clin Oncol 18: 1164-1172, 2000
6. Bishoff JT, Reyes A, Thompson IM, Harris MJ, St Clair SR, Gomella L, Butzin CA: Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: Development of a system of patient selection. Urology 45: 270-274, 1995
7. Narayan P, Fournier G, Gajendran V, Leidich R, Lo R, Wolf JS Jr, Jacob G, Nicolaisen G, Palmer K, Freiha F: Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph-node metastases in prostate cancer. Urology 44: 519-524, 1994
8. Partin A, Kattan M, Subong E, Walsh P, Wojno K, Oesterling J, Scardino P, Pearson J: Combination of prostate-specific antigen, clinincal stage, and Gleason Score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277: 1445-1551, 1997
9. Meng MV, Carroll PR: When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis. J Urol 164: 1235-1240, 2000
10. Frank E, Sood OP, Torjman M, Mulholland SG, Gomella LG: Postoperative epidural analgesia following radical retropubic prostatectomy: Outcome assessment. J Surg Oncol 67: 117-120, 1998
11. Gottschalk A, Smith DS, Jobes DR, Kennedy SK, Lally SE, Noble VE, Grugan KF, Seifert HA, Cheung A, Malkowicz SB, Gutsche BB, Wein AJ: Preemptive epidural analgesia and recovery from radical prostatectomy: A randomized controlled trial (see comments). Jama 279: 1076-1082, 1998
12. Reinhart DI: Minimising the adverse effects of ketorolac. Drug Saf 22: 487-497, 2000
13. Goad JR, Eastham JA, Fitzgerald KB, Kattan MW, Collini MP, Yawn DH, Scardino PT: Radical retropubic prostatectomy: Limited benefit of autologous blood donation. J Urol 154: 2103-2109, 1995
14. O'Hara JF Jr, Sprung J, Klein EA, Dilger JA, Domen RE, Piedmonte MR: Use of preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy. Urology 54: 130-134, 1999
15. Noldus J, Gonnermann D, Huland H: Autologous blood transfusion in radical prostatectomy: Results in 263 patients. Eur Urol 27: 213-217, 1995
16. Walsh PC: Radical prostatectomy: A procedure in evolution. Semin Oncol 21: 662-671, 1994
17. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years (see comments). J Urol 152: 1831-1836, 1994
18. Steiner MS: The puboprostatic ligament and the male urethral suspensory mechanism: An anatomic study. Urology 44: 530-534, 1994
19. Koch MO: Management of the dorsal vein complex during radical retropubic prostatectomy. Semin Urol Oncol 18: 33-37, 2000
20. Catalona WJ, Carvalhal GF, Mager DE, Smith DS: Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 162: 433-438, 1999
21. Ghavamian R, Zincke H: An updated simplified approach to nerve-sparing radical retropubic prostatectomy. BJU Int 84: 160-163, 1999
22. Klotz L: Neurostimulation during radical prostatectomy: Improving nerve-sparing techniques. Semin Urol Oncol 18: 46-50, 2000
23. Klotz L: Intraoperative cavernous nerve stimulation during nerve sparing radical prostatectomy: How and when? Curr Opin Urol 10: 239-243, 2000
24. Cangiano TG, Litwin MS, Naitoh J, Dorey F, deKernion JB: Intraoperative frozen section monitoring of nerve sparing radical retropubic prostatectomy. J Urol 162: 655-658, 1999
25. Steiner MS: Anatomic basis for the continence-preserving radical retropubic prostatectomy. Semin Urol Oncol 18: 9-18, 2000
26. Soloway MS, Neulander E: Bladder-neck preservation during radical retropubic prostatectomy. Semin Urol Oncol 18: 51-56, 2000
27. DeMarco RT, Bihrle R, Foster RS: Early catheter removal following radical retropubic prostatectomy. Semin Urol Oncol 18: 57-59, 2000
28. Weldon VE, Tavel FR: Potency-sparing radical perineal prostatectomy: Anatomy, surgical technique and initial results. J Urol 140: 559-562, 1988
29. Paulson DF: Radical perineal prostatectomy. Urol Clin N Am 7: 847, 1980
30. Belt E: Radical perineal prostatectomy in early carcinoma of the prostate. J Urol 48: 287, 1942
31. Scolieri MJ, Resnick MI: The technique of radical perineal prostatectomy. Urol Clin N Am 28: 521-533, 2001
32. Sullivan LD, Weir MJ, Kinahan JF, Taylor DL: A comparison of the relative merits of radical perineal and radical retropubic prostatectomy. BJU International 85: 95-100, 2000
33. Frazier HA, Robertson JE, Paulson DF: Radical prostatectomy: The pros and cons of the perineal versus retropubic approach. J Urol 147: 888-890, 1992
34. Weldon VE, Tavel FR, Neuwirth H, Cohen R: Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 153: 1565-1569, 1995
35. Lance RS, Freidrichs PA, Kane CJ, Powell CR, Pulos E, Moul JW, Mcleod DG, Cornum RL, Thrasher JB: A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the uniformed services urology research group. BJU International 87: 61-65, 2001
36. Zippe CD, Rackley RR: Non-nerve sparing radical prostatectomy in the elderly patient: Perineal vs. retropubic approach (abstract 359). J Urol 155: 400A, 1996
37. Weldon VE, Tavel FR, Neuwirth H: Continence, potency and morbidity after radical perineal prostatectomy. J Urol 153: 1565, 1997
38. Thomas R, Steele R, Smith R: One-Stage laparoscopic pelvic lymphadenectomy and radical perineal prostatectomy. J Urol 152: 1174, 1994
39. Gibbons RP, Correa RJJ, Brannen GE: Total prostatectomy for localized prostate cancer. J Urol 131: 73, 1984
40. Parra RO: Analysis of an experience with 500 radical perineal prostatectomies in localized prostate cancer (Abstract). J Urol 163: 284-285, 2000
41. Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148: 331, 1992
42. Stamey TA, Villers AA, McNeal JE, Link PC, Freiha FS: Positive surgical margins at radical prostatectomy: Importance of the apical dissection. J Urol 143: 1166, 1990
43. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582, 1993
44. Bishoff JT, Motley G, Optenberg SA, Stein CR, Moon KA, Browning SM, Sabanegh E, Foley JP, Thompson IM: Incidence of fecal and urinary incontinence following radical perineal and retropubic prostatectomy in a national population. J Urol 160: 454-458, 1998
45. Schuessler W, Schulman P, Clayman R, Kavoussin L: Laparoscopic radical prostatectomy: Initial short-term experience. Urology 50: 854-857, 1997
46. Guillonneau B, Cathelineau X, Barrett E, Rozet F, Vallencien G: Laparoscopic radical prostatectomy: Technical and early oncological assessment of 40 operations. Eur Urol 36: 14-20, 1999
47. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152: 1826-1830, 1994
48. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer (see comments). J Urol 152: 1850-1857, 1994
49. Zincke H, Bergstralh EJ, Blute ML, Myers RP, Barrett DM, Lieber MM, Martin SK, Oesterling JE: Radical prostatectomy for clinically localized prostate cancer: Long-term results of 1,143 patients from a single institution (see comments). J Clin Oncol 12: 2254-2263, 1994
50. Kupelian PA, Katcher J, Levin HS, Klein EA: Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol. Phys 37: 1043-1052, 1997
51. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update (see comments) (published erratum appears in JAMA 1997 July 9; 278(2): 118). Jama 277: 1445-1451, 1997
52. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P, O'Dowd GJ, Veltri RW: An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 156: 1375-1380, 1996
53. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC, Carroll PR: Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?: Data from the CAPSURE database. Urology 56: 430-435, 2000
54. Haese A, Huland E, Graefen M, Huland H: Supersensitive PSA-analysis after radical prostatectomy: A powerful tool to reduce the time gap between surgery and evidence of biochemical failure. Anticancer Res 19: 2641-2644, 1999
55. Yu H, Diamandis EP, Prestigiacomo AF, Stamey TA: Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem 41: 430-434, 1995
56. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer (see comments). J Urol 152: 1837-1842, 1994
57. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy (see comments). Jama 281: 1591-1597, 1999
58. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818-1824, 1995
59. Iselin CE, Box JW, Vollmer RT, Layfield LJ, Robertson JE, Paulson DF: Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer 83: 2353-2360, 1998
60. Trapasso JG, deKernion JB, Smith RB, Dorey F: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy (see comments). J Urol 152: 1821-1825, 1994
61. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713-725, 1993
62. Han M, Partin A, Pound C, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Am 28: 555-565, 2001
63. Patel A, Dorey F, Franklin J, deKernion JB: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen (see comments). J Urol 158: 1441-1445, 1997
64. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43: 649-659, 1994
65. Thompson IM, Middleton RG, Optenberg SA, Austenfeld MS, Smalley SR, Cooner WH, Correa RJ Jr, Miller HC Jr, Oesterling JE, Resnick MI, Wasson JH, Roehrborn CG: Have complication rates decreased after treatment for localized prostate cancer? J Urol 162: 107-112, 1999
66. Goluboff ET, Saidi JA, Mazer S, Bagiella E, Heitjan DF, Benson MC, Olsson CA: Urinary continence after radical prostatectomy: The Columbia experience. J Urol 159: 1276-1280, 1998
67. Wahle GR: Urinary incontinence after radical prostatectomy. Semin Urol Oncol 18: 66-70, 2000
68. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT: Factors predicting recovery of erections after radical prostatectomy (in process citation). J Urol 164: 1929-1934, 2000
69. Zippe CD, Jhaveri FM, Klein EA, Kedia S, Pasqualotto FF, Kedia A, Agarwal A, Montague DK, Lakin MM: Role of Viagra after radical prostatectomy. Urology 55: 241-245, 2000
70. Zippe CD, Kedia S, Kedia AW, Pasqualotto F: Sildenafil citrate (Viagra) after radical retropubic prostatectomy: Pro (editorial). Urology 54: 583-586, 1999
71. Blander DS, Sanchez-Ortiz RF, Wein AJ, Broderick GA: Efficacy of sildenafil in erectile dysfunction after radical prostatectomy (in process citation). Int J Impot Res 12: 165-168, 2000
72. Kim ED, Scardino PT, Hampel O, Mills NL, Wheeler TM, Nath RK: Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol 161: 188-192, 1999
73. Witjes WP, Schulman CC, Debruyne FM: Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The european study group on neoadjuvant treatment of prostate cancer. Urology 49: 65-69, 1997
74. Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, Baert L: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 154: 429-434, 1995
75. Soloway M, Pareek K, Rooholiah S, Wajsman Z, Mcleod D, Wood DJ, Puras-Baez A: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167: 112-116, 2002
76. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD: Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Semin Urol Oncol 14: 39-45; Discussion 46-47, 1996
77. Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD: Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Evaluation of risk for biochemical recurrence at 5-year follow-up. Urology 56: 289-294, 2000
78. Gleave M, Goldenberg S, Chin J, Warner J, Saad F, Klotz L, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 166: 500-507, 2001
79. McCarthy JF, Catalona WJ, Hudson MA: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment. J Urol 151: 1575-1578, 1994
80. Petrovich Z, Lieskovsky G, Langholz B, Luxton G, Jozsef G, Skinner DG: Radiotherapy following radical prostatectomy in patients with adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 21: 949-954, 1991
81. Zietman AL, Coen JJ, Shipley WU, Althausen AF: Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: Analysis of freedom from PSA failure. Urology 42: 292-298; Discussion 298-299, 1993
82. Coetzee LJ, Hars V, Paulson DF: Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 47: 232-235, 1996
83. Gibbons RR Cole BS, Richardson RG, Correa RJ Jr, Brannen GE, Mason JT, Taylor WJ, Hafermann MD: Adjuvant radiotherapy following radical prostatectomy: Results and complications. J Urol 135: 65-68, 1986
84. Syndikus I, Pickles T, Kostashuk E, Sullivan LD: Post-operative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control (see comments). J Urol 155: 1983-1986, 1996
85. Fleming I, Cooper J, Henson D: Manual for Staging of Cancer Lippincott-Raven, Philadelphia, 1997
86. Raboy A, Albert P, Ferzli: Early experience with extraperitoneal endoscopic radial retropubic prostatectomy. Surg Endosc 1264-1267, 1998
87. Guillonneau B, Vallencien G: Laparoscopic radical prostatectomy: The Montsouris experience. J Urol 163: 418-422, 2000
88. Abbou CC, Salomon L, Hoznek A, Antiphon P, Cicco A, Saint F, Alame W, Bellot J, Chopin DK: Laparoscopic radical prostatectomy: Preliminary results. Urology 55: 630-634, 2000
89. van Velthoven R, Peltier A, Hawaux E, Vendewalle J: Transperitoneal laparoscopic anatomic radical prostatectomy, preliminary results. J Urol 163: 141, Abstract 621, 2000
90. Rassweiler J, Sentker L, Seeman O, Hatzinger M, Rumpelt H: Laparoscopic radical prostatectomy with the heilbronn technique: An analysis of the first 180 cases. J Urol 166: 2101-2108, 2001
91. Turek I, Degar S, Winkelman B, Loening S: Laparoscopic radical prostatectomy- the Berlin experience. J Urol 165: 326, Abstract 1340, 2001
92. Zippe CD, Meraney A, Sung G, Gill I: Laparoscopic prostatectomy in the USA: Cleveland clinic series of 50 patients. J Urol, 165: 326, abstract 1341, 2001
93. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer Canadian Urologic Oncology Group (see comments). J Urol 156: 873-877, 1996
94. Schulman C, Debruyne F, Forster G, Selvaggi F, Zlotta A, Witjes W: 4-year follow-upresults of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol 38: 706-713, 2000
95. Soloway M, Sharifi R, Wajsman Z, Mcleod DG, Wood DJ, Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154: 424-428, 1995
96. Labrie F, Cusan L, Gomez J, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Candas B: Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44A: 29-36, 1994
97. Lee F, Siders D, McHug T, Solomon M, LKlamerus M: Long term follow-up of stages T@-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. Anticancer Res 17: 1507-1510, 1997
98. Fair WR, Scher HI: Neoadjuvant hormonal therapy plus surgery for prostate cancer. The MSKCC experience. Surg Oncol Clin N Am 6: 831-846, 1997
99. Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, Russo P, Soloway SM, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg CB, Heston WD, Reuter VE: The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 49: 46-55, 1997
100. Meyer F, Moore L, Bairati I, Lacombe L, Tetu B, Fradet Y: Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 162: 2024-2028, 1999
101. Pedersen K, Lundberg S, Hugosson J: Neoadjuvant hormonal treatment with triptorelin versus no treatment prior to radical prostatectomy: A prospective randomized multicenter study. J Urol 153: 391A, 1995
102. Aus G, Abrahamsson P-A, Ahlgren G: Hormonal treatment before radical prostatectomy: A 3-year followup. J Urol 159: 2013-2016, 1998
103. Klotz LH, Goldenberg SL, Jewett M, Barkin J, Chetner M, Fradet Y, Chin J, Laplante S: CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. Urology 53: 757-763, 1999
104. Soloway M: Radical prostatectomy alone versus radical prostatectomy preceded by three months androgen blockade in cT2b prostate cancer: 60 mon results. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 167: 113-116, 2002